TAK stock reports VERDICT data ahead of the Xetra open
Published on 10/20/2026 at 08:48 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSClinical update and earnings date
- A Takeda Phase 4 trial reported a hazard ratio of 0.33 on October 19, 2026.
- Takeda’s fiscal 2026 second-quarter results call is scheduled for October 29, 2026.
- TAK stock trades pre-market at EUR 17.75 at 8:44 a.m. CEST at Lang & Schwarz on October 20, 2026.
On October 19, 2026, Takeda announced new VERDICT trial data showing that treating adults with ulcerative colitis to a corticosteroid-free disease-clearance target produced a longer time to the first ulcerative-colitis-related complication than symptomatic remission alone, according to the company’s release. Takeda stock trades pre-market at EUR 17.75 at 8:44 a.m. CEST at Lang & Schwarz on October 20, 2026.
Ulcerative colitis trial update
The Phase 4 VERDICT study met its primary endpoint. The reported hazard ratio was 0.33, with a 95 percent confidence interval of 0.17 to 0.67 and a P value of 0.0014. Takeda said the findings represented a nearly 70 percent reduction in ulcerative-colitis complication risk and that more than half of ENTYVIO patients who met their assigned treatment target achieved disease clearance by Week 16. Results were presented at United European Gastroenterology Week 2026 and published in the United European Gastroenterology Journal. The company’s release said the study was conducted in collaboration with Alimentiv.
Ahead of the Xetra open
The bid was EUR 17.60 and the ask was EUR 17.90, a 1.69 percent spread based on the displayed pre-market prices. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of TAK stock.
Takeda and the next company date
Takeda develops and commercializes medicines in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, according to its company materials. Takeda will host a call on October 29, 2026, to present its fiscal 2026 second-quarter results, the company said in its October 15 announcement. The relevant benchmark for Takeda’s home market is Japan’s Nikkei 225. Market context: Market report Nikkei 225.
